Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$106.68B |
$54.42
+3.84%
|
|
CVS
CVS Health Corporation
CVS retails OTC analgesics and related pain relief products.
|
$100.73B |
$79.78
+0.45%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$78.57B |
$754.42
+1.77%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$57.58B |
$201.06
+0.08%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX launched the IDEXX Cancer Dx panel, a cancer diagnostic test aligned with companion diagnostics for oncology.
|
$56.34B |
$699.46
-0.67%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$52.59B |
$120.91
+1.90%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$52.50B |
$846.03
-3.63%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$52.11B |
$394.29
-0.82%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$47.32B |
$199.49
+0.66%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$45.43B |
$14.55
+1.57%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$43.47B |
$9.81
+3.10%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$41.64B |
$196.30
-0.36%
|
|
A
Agilent Technologies, Inc.
BIOVECTRA acquisition expands Agilent's contract manufacturing capabilities (CDMO) for advanced modalities.
|
$39.68B |
$140.31
+0.45%
|
|
ALC
Alcon Inc.
Alcon markets ophthalmic drugs and prescription eye drops like Tryptyr.
|
$38.97B |
$79.14
+0.43%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare markets proprietary radiopharmaceuticals (e.g., Flyrcado) and radiopharmaceutical diagnostics.
|
$38.33B |
$84.43
+0.56%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$37.78B |
$224.10
+0.83%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$35.14B |
$309.05
-3.14%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.26B |
$17.29
-0.26%
|
|
BIIB
Biogen Inc.
Biogen's LEQEMBI is an Alzheimer's disease therapeutic, a direct product the company manufactures and sells.
|
$25.53B |
$175.19
+0.63%
|
|
JBL
Jabil Inc.
Aseptic filling and dry oral dosage capabilities via Pharmaceutics International (Pii) reflect contract manufacturing services in pharma.
|
$23.86B |
$222.22
-0.07%
|
|
BNTX
BioNTech SE
The company is pivoting toward oncology with immunotherapies, making Biotech - Oncology a core product/business focus.
|
$22.73B |
$94.09
-0.76%
|
|
UTHR
United Therapeutics Corporation
UTHR's core PAH/CV therapy portfolio centers on prostacyclin cardiovascular drugs, including Tyvaso, Remodulin, Orenitram, and Ralinepag (where applicable).
|
$22.34B |
$497.83
+0.78%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$21.95B |
$262.34
-0.70%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$20.82B |
$293.04
-0.90%
|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$20.72B |
$31.43
+0.40%
|
|
WST
West Pharmaceutical Services, Inc.
West generates revenue from contract manufacturing services, moving towards higher-margin opportunities.
|
$19.24B |
$271.90
+1.62%
|
|
EXAS
Exact Sciences Corporation
Oncotype DX is a genomic assay used as a companion diagnostic in oncology, and the company discusses companion diagnostic capabilities and leadership in Precision Oncology.
|
$19.22B |
$101.56
+0.06%
|
Showing page 2 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
